Centessa Pharmaceuticals reported intriguing Phase IIa proof-of-concept data last week for SerpinPC as prophylaxis for patients with severe haemophilia A or B that could, in theory anyway, be an option regardless of inhibitor status. The company hopes to begin pivotal testing of the activated protein C (APC) inhibitor next year.
To provide FirstWord readers with rapid feedback on the role that SerpinPC could play in treating haemophilia, we are hosting an expert call with a key opinion leader (KOL) this week.
Key topics that will be discussed during the call include, among other things… thoughts on SerpinPC’s mechanism of action as an APC inhibitor; what stands out most about the top-line Phase IIa trial and self-reported annualised bleed reductions of between 70% and 88%; what will you be most interested to see when Centessa reveals the detailed dataset; what are your biggest questions about SerpinPC at this point; what are the biggest unmet needs in haemophilia and does SerpinPC tick any of these boxes; how much more attractive is SerpinPC given its potential for use in haemophilia A and B, and regardless of inhibitor status; could a less frequent dosing schedule significantly impact use of the product; are you more or less optimistic about SerpinPC relative to agents targeting TFPI or antithrombin; and where do you see SerpinPC fitting into the treatment algorithm and with what products is it likely to compete?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the use of SerpinPC and other haemophilia therapeutics.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord Pharma would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.